These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 10470190)
21. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
22. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
23. Significance of some tumor markers in differential diagnosis of ovarian tumor. Zakrzewska I; Borawska R; Poznański J; Maćkowiak B Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438 [TBL] [Abstract][Full Text] [Related]
24. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays. Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806 [TBL] [Abstract][Full Text] [Related]
25. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer]. Liu W Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823 [TBL] [Abstract][Full Text] [Related]
26. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis. Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352 [TBL] [Abstract][Full Text] [Related]
27. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245 [TBL] [Abstract][Full Text] [Related]
29. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784 [TBL] [Abstract][Full Text] [Related]
30. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Padungsutt P; Thirapagawong C; Senapad S; Suphanit I Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437 [TBL] [Abstract][Full Text] [Related]
31. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176 [TBL] [Abstract][Full Text] [Related]
32. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173 [TBL] [Abstract][Full Text] [Related]
33. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538 [TBL] [Abstract][Full Text] [Related]
34. [The clinical value of tissue polypeptide antigen in ovarian carcinoma]. Wu L; Sun J; Wang X Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428 [TBL] [Abstract][Full Text] [Related]
35. Pre-operative prediction of serum CA125 level in women with ovarian masses. Benjapibal M; Neungton C J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413 [TBL] [Abstract][Full Text] [Related]
36. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer. Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372 [TBL] [Abstract][Full Text] [Related]
37. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164 [TBL] [Abstract][Full Text] [Related]
38. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment]. Shi W; Zhang YJ; Jiang CY Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875 [TBL] [Abstract][Full Text] [Related]
39. [Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary]. Chen C; Li JD; Huang H; Feng YL; Wang LH; Chen L Ai Zheng; 2008 Jan; 27(1):92-5. PubMed ID: 18184473 [TBL] [Abstract][Full Text] [Related]
40. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]